## Abstract We have analyzed the gene modulation induced by zoledronic acid (ZOL) in androgen‐resistant prostate cancer PC3 cells with cDNA microarray platform to identify new molecular targets of ZOL in prostate cancer. The gene coding for cysteine‐rich, angiogenic inducer, 61 (CYR61) resulted hig
Anticancer effects of zoledronic acid against human osteosarcoma cells
✍ Scribed by B. Kubista; K. Trieb; F. Sevelda; C. Toma; F. Arrich; P. Heffeter; L. Elbling; H. Sutterlüty; K. Scotlandi; R. Kotz; M. Micksche; W. Berger
- Publisher
- Elsevier Science
- Year
- 2006
- Tongue
- English
- Weight
- 355 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0736-0266
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Based on neoadjuvant chemotherapy, the prognosis of osteosarcoma patients has improved dramatically. However, due to therapy resistance in patient subgroups, the development of new treatment strategies is still of utmost importance. The aim of our study was to test the effects of the nitrogen‐containing bisphosphonate zoledronic acid (ZOL) on osteosarcoma cell lines (N = 9). Exposure to ZOL at low micromolar concentrations induced a dose‐ and time‐dependent block of DNA synthesis and cell cycle progression followed by microfilament breakdown and apoptosis induction. The ZOL‐induced cell cycle accumulation in S phase was accompanied by significant changes in the expression of cyclins and cyclin‐dependent kinase inhibitors with a prominent loss of cyclin E and D1. ZOL not only inhibited growth but also migration of osteosarcoma cells. The mevalonate pathway intermediary geranyl‐geraniol (GGOH) but not farnesol (FOH) significantly inhibited the anticancer effects of ZOL against osteosarcoma cells. Correspondingly, ZOL sensitivity correlated with the blockade of protein geranylgeranylation indicated by unprenylated Rap1. Overexpression of even high levels of P‐glycoprotein, as frequently present in therapy‐resistant osteosarcomas, did not impair the anticancer activity of ZOL. Summarizing, our data suggest that ZOL, which selectively accumulates in the bone, represents a promising agent to improve osteosarcoma therapy. © 2006 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res
📜 SIMILAR VOLUMES
## Abstract Nine osteosarcoma cell lines, originally developed from six osteosarcoma tumours in five patients, and two cell lines of non‐tumour origin (glia and fibro‐blast) were grown __in vitro__ in the presence of human leukocyte interferon (L‐IF). L‐IF exerted a dose‐dependent inhibition of gro
Expression of urokinase-type plasminogen activator (u-PA) strongly correlates with a malignant tumor cell phenotype. In the multistep process of metastasis, different cellular functions are influenced by urokinase. The enzyme is known to be effective via both proteolytical and signal transduction me
## Abstract The CD40‐ligand (CD40L) is a key molecule for the activation of dendritic cells (DCs), followed by the induction of DC maturation and cytokine production. Here we found that DC infected with adenovirus vector encoding human CD40L (CD40L‐DC) displayed significantly higher levels of immun
## Abstract Locally applied antibiotic therapy is gaining popularity for the treatment of infections associated with open fractures and posttraumatic osteomyelitis. With use of local techniques, ciprofloxacin levels as high as 1,300 μg/ml. or over 200 times the bone levels achieved with intravenous